Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment

Merck & Co Inc (NYSE:MRK) and Jiangsu Hengrui Pharmaceuticals Co., Ltd on Tuesday entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China.

Lipoprotein (a), or Lp(a), is a type of lipoprotein produced in the liver that carries cholesterol, fats, and proteins in the blood.

Also Read: Pharmaceutical Firms Say UK Investment Is ...